장중 · Aug 18, 2026, EDT
·
정보기술
·
강한 매수
Pharming Group N.V. announces that the European Commission has granted marketing authorization for Joenja (leniolisib)
[출처/시간] Briefing.com - 3:34 PM ET, 05/22/2026 Joenja is an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Joenja is the first and only approved treatment for APDS in the European Union.The first European launch is expected in Germany in Q3 2026, with additional launches anticipated pen
뉴스
|
admin
|
May 22, 2026
[출처/시간] Briefing.com - 3:34 PM ET, 05/22/2026
Joenja is an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Joenja is the first and only approved treatment for APDS in the European Union.The first European launch is expected in Germany in Q3 2026, with additional launches anticipated pending completion of national reimbursement negotiations.
ADVERTISEMENT
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.